Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 23;13:1037214. doi: 10.3389/fimmu.2022.1037214

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Räuber, Willison, Korsen, Kölsche, Golombeck, Plaack, Schüller, Huntemann, Rolfes, Schroeter, Nelke, Regner-Nelke, Förster, Ringelstein, Barnett, Hartung, Aktas, Albrecht, Ruck, Melzer, Meuth and Kremer

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Vaccine-based clinical protection of MS patients receiving ocrelizumab. (A) Differences in vaccine doses between OCR-pwMS infected with SARS-CoV-2 and non-infected patients; (B) Comparison of age between SARS-CoV-2-infected OCR-pwMS and non-infected patients. (C) Differences in sex between non-infected and infected OCR-pwMS; (D) Comparison of vaccine doses between OCR-pwMS with and without symptomatic SARS-CoV-2 infection; (E) Differences in age between OCR-pwMS with and without symptomatic SARS-CoV-2 infection; (F) Differences in sex between OCR-pwMS with and without symptomatic SARS-CoV-2 infection. *p ≤ 0.05, **p ≤ 0.01. OCR, ocrelizumab; SARS-CoV-2, severe acute respiratory syndrome.